Selank
A Russian-developed heptapeptide anxiolytic, registered in Russia. Trials exist but are small, largely Russian-language, and not independently replicated.
Cognitive & Neuro
GB-115
A Russian-developed dipeptide anxiolytic acting on cholecystokinin signalling. Published human data is confined to a small number of Russian-language studies.
Overview
Cholecystokinin is best known as a gut hormone, but in the brain it also drives anxiety and, at high enough doses, panic. Compounds that block the CCK-B receptor have long been investigated as anxiolytics that would not carry benzodiazepine baggage. GB-115 is a very short peptide designed around that idea, from the same Russian institute that produced Selank and several other dipeptide drugs.
A retro-analogue dipeptide of the cholecystokinin-4 C-terminal fragment, amyloid-N-phenylhexanoyl-glycyl-L-tryptophan amide, developed at the Zakusov Institute of Pharmacology. Acts as a CCK-B receptor ligand with reported anxiolytic and antidepressant-like activity in rodent conflict and forced-swim models, and reported attenuation of morphine and ethanol withdrawal signs. Human data is limited to early-phase Russian studies. Mechanistic characterisation outside the originating institution is sparse, and no independent replication of the clinical findings exists in the English-language literature.
Research areas
AnxietyWithdrawal syndromesCCK signalling
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Intraperitoneal dosing in rodent conflict and elevated plus-maze models | Zakusov Institute preclinical series |
Trial status
Early-phase Russian clinical work. No registered trials in the US or EU and no independent replication.
Reported safety signals
- Human safety data outside a small Russian research programme is effectively absent.
- No independent pharmacology or toxicology has been published in the international literature.
- Anything sold under this name has no verified identity.
Common questions
Why is there so little information about GB-115?
Almost all of it was produced by a single Russian institute and published in Russian-language journals. Nothing has been independently replicated internationally, and there is no registered Western trial programme.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →